opening briefing- dr. john holaday, page-5

Agree Stu,

I was happy with what I heard.

The post-CRL crash was to me about the possibility of seeing additional trial, substantially delayed timeline and dilution through CR. IMO all now significantly diminished risks. Traded back up to 92c on 9th July on the initial recovery post the late-June wipeout. Yet no reaction now?

I think the instos are gunshy, and will wait until confirmation that the resubmission is in later in the year before buying back in.

Until then, IMO a good risk/reward prospect for a 12 month timeframe post potential approval(DYOR!).

GLTA